Dance Pharma, Aerogen plan to develop inhaled insulin delivery device

Dance has been granted exclusive worldwide license to Aerogen’s aerosol technology for insulin delivery and the other terms of the agreement were not disclosed.

Dance Pharma CEO John Patton said Dance’s team of inhaled insulin experts considered all potential aerosol technologies worldwide and chose Aerogen’s technology because they are convinced it’s the best, most patient-friendly technology for their first inhaled insulin product.

"Our mission at Dance is to provide inhaled insulin in small, discreet, pain-less, and low cost form to patients throughout the world," Patton said.